Search results for: France
Filter search results
Understanding the Full Value of Long-Acting Therapies: less is more?
7 May 2025
…often overlooked. Countries with more flexible HTA frameworks, like Canada and the UK, are better positioned to capture these broader value elements than others like Germany and France. Stakeholder collaboration…
Altering the trajectory of HIV in Europe
22 May 2025
…to rise, leading to increases in healthcare costs and broader societal impact. The total estimated cost of HIV care between 2025 and 2030 is estimated at €56.7bn across France, Germany,…
New OHE Study Compares Decisions by Five HTA Agencies on Oncology Meds
31 January 2013
…in a selection of industrialised countries: Australia, Canada, France, Scotland, and the United Kingdom (England and Wales). The aims of the study are to identify the key determinants of decisions…
Are Recommendations for HTA of Gene Therapies Being Achieved?
11 September 2023
…develop country scorecards exploring the extent to which these recommendations are being achieved in eleven countries. The countries considered were: Australia, Canada, Denmark, England, France, Germany, Italy, the Netherlands, Spain,…
Adult vaccination programmes deliver socio-economic benefits up to 19 times initial investment, according to new report
18 April 2024
…at the delivery of vaccine programmes in countries that represent a range of healthcare systems, demographics, and vaccine schedules – Australia, Brazil, France, Germany, Italy, Japan, Poland, South Africa, Thailand,…
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
1 January 2022
…(HTA) agency determines how these challenges are currently addressed. This report provides an analysis of HTA agency assessments and reimbursement decisions for entrectinib and larotrectinib across England, Germany, France, Canada,…
The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries
5 January 2018
…this debate, and of how IBP has been implemented – in its various forms – to date in the U.S., France, Germany, Italy, Spain and the UK. IBP increases the…
The Life Cycle of Pharmaceuticals: A Cross-National Perspective
1 April 2002
…contribution to the methodology of cross-national comparisons for medicines. In this study we use comprehensive data on outpatient sales for all drugs in seven countries (Canada, France, Germany, Italy, Japan,…
Pharmaceuticals in seven nations
1 May 1985
…pharmaceutical industry, with particular reference to its structure and activities in seven countries – the Federal Republic of Germany, France, Italy, Japan, Switzerland, the United Kingdom and the United States….